Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more
Market Cap & Net Worth: Botanix Pharmaceuticals Limited (BXPHF)
Botanix Pharmaceuticals Limited (PINK:BXPHF) has a market capitalization of $492.53 Million ($492.53 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #17866 globally and #6730 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Botanix Pharmaceuticals Limited's stock price $0.25 by its total outstanding shares 1970102820 (1.97 Billion).
Botanix Pharmaceuticals Limited Market Cap History: 2019 to 2025
Botanix Pharmaceuticals Limited's market capitalization history from 2019 to 2025. Data shows growth from $157.61 Million to $492.53 Million (4.09% CAGR).
Botanix Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Botanix Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
85.55x
Botanix Pharmaceuticals Limited's market cap is 85.55 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $157.61 Million | $4.69 Million | -$17.04 Million | 33.63x | N/A |
| 2020 | $216.71 Million | $7.57 Million | -$16.73 Million | 28.61x | N/A |
| 2021 | $78.61 Million | $6.89 Million | -$3.33 Million | 11.41x | N/A |
| 2022 | $39.40 Million | $2.75 Million | -$13.17 Million | 14.30x | N/A |
| 2023 | $236.41 Million | $3.77 Million | -$9.15 Million | 62.67x | N/A |
| 2024 | $472.82 Million | $2.07 Million | -$13.87 Million | 228.47x | N/A |
| 2025 | $492.53 Million | $5.76 Million | -$86.40 Million | 85.55x | N/A |
Competitor Companies of BXPHF by Market Capitalization
Companies near Botanix Pharmaceuticals Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Botanix Pharmaceuticals Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Botanix Pharmaceuticals Limited Historical Marketcap From 2019 to 2025
Between 2019 and today, Botanix Pharmaceuticals Limited's market cap moved from $157.61 Million to $ 492.53 Million, with a yearly change of 4.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $492.53 Million | +4.17% |
| 2024 | $472.82 Million | +100.00% |
| 2023 | $236.41 Million | +500.00% |
| 2022 | $39.40 Million | -49.87% |
| 2021 | $78.61 Million | -63.73% |
| 2020 | $216.71 Million | +37.50% |
| 2019 | $157.61 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Botanix Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $492.53 Million USD |
| MoneyControl | $492.53 Million USD |
| MarketWatch | $492.53 Million USD |
| marketcap.company | $492.53 Million USD |
| Reuters | $492.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.